NEWS
‘The Price of Business’: Discussing Today’s Political and Economic Environment
On June 8, Alex Brill joined Kevin Price on ‘The Price of Business’ discussing today’s political and economic environment. Brill shared his sentiments on the economic outlook.
New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology
MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.”
Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded
In response to the FTC’s request for information regarding the business practices of pharmacy benefit managers (PBMs) and their impact on pharmacies and consumers, MGA’s Alex Brill submitted a letter detailing his findings.
Do Tax Cuts Cause Inflation? Alex Brill on ‘The Price of Business’
On May 11, Alex Brill joined Kevin Price on his radio show, “The Price of Business,” to talk about whether tax cuts cause inflation. The short answer is: It depends.
‘The Price of Business’: Alex Brill Talks Rising Inflation
On April 21, Alex Brill made a special appearance on “The Price of Business” radio show to talk about the sharp rise of inflation and its effects on small businesses and individuals earning low wages.
Massachusetts’s Proposed ‘Millionaires’ Tax’ Will Push up the Federal Deficit
There is a proposed tax change in Massachusetts that should have all who are interested in fiscal policy concerned. In November, Bay State voters will decide whether to adopt an amendment to the state constitution imposing a 4 percent surtax on annual taxable income above $1 million starting in 2023.
Charitable Giving is Good. Be Smart About how to Encourage It.
In 2020, Americans’ individual charitable giving reached $324 billion, a record high and a 2.2 percent increase from 2019. While the pandemic imposed great costs on our society, many households shared their resources with others, including religious, educational, and human service organizations.
MGA Report Cited in Forbes Article on Rising Prescription Drug Prices
In his Forbes article, Ike Brannon discusses the blame game being played in Washington in regards to skyrocketing drug prices. MGA’s report “Understanding Drug Rebates and Their Role in Promoting Competition” was utilized by Brannon to bolster the argument that it is the drug companies who are responsible for drug pricing.
New Report from MGA Examines Impact of Rebates on Drug Pricing, Competition
MGA has released a new report today, “Understanding Drug Rebates and Their Role in Promoting Competition,” authored by founder and CEO Alex Brill.
The Great Resignation: Alex Brill Shares Insights on i24News
A record number of people are quitting their jobs across all employment sectors. Alex Brill joins i24News to discuss what the skyrocketing quit rates means for the US economy, and when we can expect the job market to return to normal.
Patent Thickets Constrain US Biosimilars Market
Biosimilars represent a significant cost-savings opportunity in the United States because they can introduce competition for some of the most expensive and widely used prescription drugs on the market: originator biologics. Several market and regulatory barriers have slowed biosimilar market entry and uptake in the United States.
Alex Brill Talks Rising Inflation and Corporate Taxes on CNBC’s ‘Squawk Box’
On October 15th, Alex Brill made a special appearance on CNBC’s “Squawk Box” to discuss President Biden’s corporate tax increase and the effects of rising inflation on the U.S. economy.
IAM Quotes MGA Report in Article Discussing the Problem of Patent Thickets
In his article for Intellectual Asset Management (IAM), Life Sciences Reporter Adam Houldsworth discusses the weaknesses in the US patent system that enable the “thorny” problem of patent thickets. MGA’s report, “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” was featured heavily in the article to provide evidence of the growing problem.
Alex Brill Joins Panel Discussion on Tax Policy in the Build Back Better Act
Three policy experts join Richard Rubin of The Wall Street Journal to examine the current iteration of the Build Back Better Act.
Pension Smoothing – The Budget Gimmick That Will Not Die
The bipartisan infrastructure bill approved by the Senate on August 10 includes a number of budget gimmicks that help make it look fully “paid for.” One of the gimmicks is pension smoothing, which allows private companies to make smaller contributions to their defined-benefit pension plans, thereby endangering the plans’ financial viability over time.
- Implications of Cannabis Legalization for the US Federal Budget
- Biden Budget Proposes a Step Toward Biologic Drug Competition
- MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing Tackling the Tax Gap
- The Next Tax Fight: SALT
- Alex Brill on Single-Payer Health Care System and Drug Costs
- New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases
- The Threat to Preferred Pharmacy Networks
- Alex Brill mentioned on MSN
- Alex Brill Speaks on Consequences of Proposed PBM Constraints
